Table 3 Comparison of the use of medications between clinics with heart failure with reduced ejection fraction (EF < 40) patients
Use of medications | Total (n = 489) | MACS (n = 193) | GCHFS (n = 296) | P-value |
|---|---|---|---|---|
Contraindications for ACEIs | 69 (14.1) | 44 (23.0) | 25 (8.4) |  < .001*** |
Rate of appropriate use of ACEIs | 280 (67.0) | 97 (65.1) | 183 (67.5) | .617 |
Contraindications for MTD of ACEIs | 69 (14.1) | 44 (23.0) | 25 (8.4) |  < .001*** |
Rate of appropriate use of MTD of ACEIs | 193 (46.0) | 64 (43.0) | 129 (48.0) | .325 |
Target dose used for ACEIs | 175 (36.0) | 60 (31.1) | 115 (39.0) | .080 |
Rate of appropriate use of ACEIs/ARBs | 297 (71.0) | 102 (68.4) | 195 (72.0) | .438 |
Rate of appropriate use of MTD of ACEIs/ARBs | 210 (50.0) | 69 (46.3) | 141 (52.0) | .264 |
Target dose of ACEIs/ARBs | 203 (41.5) | 71 (37.0) | 132 (45.0) | .157 |
Contraindications for β-blockers | 11 (2.2) | 9 (5.0) | 2 (1.0) | .006** |
Rate of appropriate use of β-blockers | 421 (88.1) | 153 (83.1) | 268 (91.1) | .008** |
Contraindications for MTD of β-blockers | 11 (2.2) | 9 (5.0) | 2 (1.0) | .006** |
Rate of appropriate use of MTD of β-blockers | 197 (41.2) | 58 (31.5) | 139 (47.3) |  < .001*** |
Target dose used for β-blockers | 151 (31.0) | 42 (22.0) | 109 (37.0) |  < .001*** |
MRA contraindications | 34 (7.0) | 31 (16.1) | 3 (1.0) |  < .001*** |
MRA used without contraindications | 246 (50.3) | 62 (32.1) | 184 (62.2) |  < .001*** |
Diuretics contraindications | 2 (0.41) | 2 (1.0) | 0 (0) | – |
Diuretics used without contraindications | 419 (86.0) | 162 (84.0) | 257 (87.0) | .373 |
Digoxin contraindications | 7 (6.0) | 2 (1.0) | 5 (1.7) | .552 |
Digoxin use without contraindications | 112 (25.0) | 57 (30.0) | 65 (22.0) | .059 |
Use of digoxin in chronic atrial fibrillation | 85 (70.0) | 47 (82.5) | 38 (58.5) | .004** |